Publikationen in Zusammenarbeit mit Forschern von Université Catholique de Louvain (39)

2024

  1. The science of micronutrients in clinical practice – Report on the ESPEN symposium

    Clinical Nutrition

2023

  1. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267

  2. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

    The Lancet, Vol. 401, Núm. 10370, pp. 49-59

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    Journal of Clinical Oncology, Vol. 32

  3. Nutritional management of individuals with obesity and COVID-19: ESPEN expert statements and practical guidance

    Clinical Nutrition, Vol. 41, Núm. 12, pp. 2869-2886

  4. Prevalence and Disease Spectrum of Extracoronary Arterial Abnormalities in Spontaneous Coronary Artery Dissection

    JAMA Cardiology, Vol. 7, Núm. 2, pp. 159-166

2021

  1. A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline

    Leukemia, Vol. 35, Núm. 11, pp. 3295-3298

  2. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

    ESMO Open, Vol. 6, Núm. 5

  3. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: Post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

    Japanese Journal of Clinical Oncology, Vol. 51, Núm. 8, pp. 1287-1297

  4. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study

    European Urology, Vol. 80, Núm. 4, pp. 497-506

  5. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial

    The Lancet Infectious Diseases, Vol. 21, Núm. 9, pp. 1313-1323

  6. Integrative transnational analysis to dissect tuberculosis transmission events along the migratory route from Africa to Europe

    Journal of travel medicine, Vol. 28, Núm. 4

  7. MPL S505C enhances driver mutations at W515 in essential thrombocythemia

    Blood Cancer Journal

2020

  1. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    European Respiratory Journal, Vol. 55, Núm. 1

  2. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients

    Journal of Crohn's and Colitis, Vol. 14, Núm. 4, pp. 480-489

  3. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1513-1525

  4. Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial

    Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197

  5. Toll-like receptor 3 increases antigen-presenting cell responses to a pro-apoptotic stimulus, yet does not contribute to systemic lupus erythematosus genetic susceptibility

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 881-890

2019

  1. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

    New England Journal of Medicine, Vol. 381, Núm. 26, pp. 2506-2518